A Phase 1 interventional study of Diclofenac Sodium Gel in Healthy, sponsored by Amzell. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-09.
Sponsored by Amzell · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to compare drug exposure from two different products (AMZ001 and Diclofenac Sodium 1% Gel) in healthy participants on Day 7 after repeated topical administrations for 7 days.
Participants will receive, in a crossover design, three different treatments
Safety and tolerability of AMZ001 will be also investigated.
On their both knees, participants will apply once daily either low dose of AMZ001 or high dose of AMZ001 for 7 consecutive days. Participants will also apply Diclofenac Sodium 1% Gel as per label information on each knee.
Intensive pharmacokinetic assessment (blood samplings) will be performed on the first day of application (Day 1) as well as on the last day of application (Day 7).
Each participant will receive each of the three treatments in a randomized manner. Between each treatment, participant will not receive any of the three tested therapies between 3 weeks before receiving the next therapy. (washout period)
Participants will stay on the clinical unit only during each period of treatment but not during washout period.
Amzell is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AMZ001 applied once daily for 7 consecutive days
Drug: Diclofenac Sodium Gel
AMZ001 applied once daily for 7 consecutive days
Drug: Diclofenac Sodium Gel
Reference product applied four-times daily for 7 consecutive days
Drug: Diclofenac Sodium Gel
Topical application on both knees
Compare Exposure to Diclofenac
Area under the curve (AUC) from time zero to 24 hours
Time frame: Day 7
Pharmacokinetic Parameter - Cmax
Maximum plasma drug concentration (Cmax)
Time frame: Day 1
Pharmacokinetic Parameter - Cmin
Minimum plasma drug concentration (Cmin)
Time frame: Day 7
Pharmacokinetic Parameter - Tmax
Time to reach maximum plasma concentration (Tmax)
Time frame: Day 7
Pharmacokinetic Parameter - Ke
Terminal disposition rate constant (Ke)
Time frame: Day 7
Pharmacokinetic Parameter - Cavg
Average plasma concentration (Cavg)
Time frame: Day 7
Pharmacokinetic Parameter - Tmax
Time to reach maximum plasma concentration
Time frame: Day 1
Pharmacokinetic Parameter - Cavg
Average plasma concentration (Cavg)
Time frame: Day 1
Local Tolerability
Incidence of application site reactions according to the terminology of the International Contact Dermatitis Research Group
Time frame: Day 1 to Day 7
| Milestone | AMZ001 Low / AMZ001 High / Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 13 | 13 | 12 |
| Completed | 12 | 12 | 11 | 13 | 13 | 11 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | AMZ001 Low / AMZ001 High / Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 11 | 13 | 13 | 11 |
| Completed | 12 | 12 | 11 | 13 | 12 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | AMZ001 Low / AMZ001 High / Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low |
|---|---|---|---|---|---|---|
| Started | 12 | 12 | 11 | 13 | 12 | 11 |
| Completed | 12 | 11 | 11 | 13 | 11 | 11 |
| Not completed | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Failure to meet continuation criteria | 0 | 1 | 0 | 0 | 0 | 0 |
Area under the curve (AUC) from time zero to 24 hours
| ng*hr/mL | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Compare Exposure to Diclofenac | 141.5 ± 89.8 | 166.1 ± 90.3 | 202.3 ± 79.4 |
Maximum plasma drug concentration (Cmax)
| ng/mL | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Cmax | 4.66 ± 122.4 | 6.22 ± 128.9 | 3.85 ± 122.2 |
Minimum plasma drug concentration (Cmin)
| ng/mL | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Cmin | 3.09 ± 96.3 | 3.38 ± 90.1 | 5.03 ± 80.1 |
Time to reach maximum plasma concentration (Tmax)
| hr | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Tmax | 8 (2 to 24) | 10 (2 to 24) | 18 (2 to 24) |
Terminal disposition rate constant (Ke)
| 1/hr | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Ke | NA ± NA | NA ± NA | NA ± NA |
Average plasma concentration (Cavg)
| ng/mL | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Cavg | 5.90 ± 89.8 | 6.92 ± 90.3 | 8.43 ± 79.4 |
Time to reach maximum plasma concentration
| hr | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Tmax | 14 (2 to 24) | 16 (4 to 24) | 20 (6 to 24) |
Average plasma concentration (Cavg)
| ng/mL | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Pharmacokinetic Parameter - Cavg | 2.59 ± 119.8 | 3.48 ± 124.8 | 1.60 ± 109.9 |
Incidence of application site reactions according to the terminology of the International Contact Dermatitis Research Group
| Participants | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| no skin reaction | 62 | 61 | 64 |
| doubtful skin reaction | 7 | 7 | 7 |
| mild skin erythema | 1 | 4 | 1 |
| strong skin erythema | 1 | 0 | 0 |
Collected over From initiation of first period (Day 1) to completion of last period (Day 98). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AMZ001 Low Dose | 0/71 (0%) | 0/71 (0%) | 7/71 (9.9%) |
| AMZ001 High Dose | 0/72 (0%) | 0/72 (0%) | 8/72 (11.1%) |
| Diclofenac Sodium 1% Gel | 0/72 (0%) | 0/72 (0%) | 5/72 (6.9%) |
| Event | AMZ001 Low Dose | AMZ001 High Dose | Diclofenac Sodium 1% Gel |
|---|---|---|---|
| Application site erythemaGeneral disorders | 0/71 | 3/72 | 1/72 |
| ErythemaSkin and subcutaneous tissue disorders | 2/71 | 1/72 | 0/72 |
| HeadacheNervous system disorders | 2/71 | 0/72 | 1/72 |
| Application site hypersensitivityGeneral disorders | 0/71 | 2/72 | 0/72 |
| Aphthous ulcerGastrointestinal disorders | 1/71 | 0/72 | 0/72 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/71 | 0/72 | 0/72 |
| Administration site drynessGeneral disorders | 1/71 | 0/72 | 0/72 |
| Application site pruritusGeneral disorders | 1/71 | 0/72 | 0/72 |
| DiarrhoeaGastrointestinal disorders | 1/71 | 1/72 | 0/72 |
| Dry mouthGastrointestinal disorders | 1/71 | 0/72 | 0/72 |
| Age, Continuous(years) | AMZ001 Low/AMZ001 High/Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low | Total |
|---|---|---|---|---|---|---|---|
| Mean | 44.0 ± 11.20 | 42.3 ± 14.69 | 36.4 ± 12.35 | 42.3 ± 10.60 | 39.8 ± 11.98 | 41.8 ± 13.47 | 41.1 ± 12.69 |
| Sex: Female, Male(Participants) | AMZ001 Low/AMZ001 High/Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 5 | 5 | 10 | 7 | 4 | 38 |
| Male | 5 | 7 | 7 | 3 | 6 | 8 | 36 |
| Ethnicity (NIH/OMB)(Participants) | AMZ001 Low/AMZ001 High/Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 5 | 8 | 4 | 4 | 27 |
| Not Hispanic or Latino | 9 | 9 | 7 | 5 | 9 | 8 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AMZ001 Low/AMZ001 High/Diclofenac | Diclofenac/AMZ001 High/AMZ001 Low | Diclofenac/AMZ001 Low/AMZ001 High | AMZ001 High/AMZ001 Low/Diclofenac | AMZ001 Low/Diclofenac/AMZ001 High | AMZ001 High/Diclofenac/AMZ001 Low | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 | 0 | 1 | 3 |
| Black or African American | 6 | 6 | 7 | 5 | 6 | 7 | 37 |
| White | 5 | 6 | 4 | 7 | 7 | 3 | 32 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2023 to primary completion in Dec 2023, 5 months.
Results were first posted in Apr 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diclofenac Sodium Gel
Amzell